LC-MS/MS method for simultaneous determination of rivaroxaban and metformin in rat plasma : application to pharmacokinetic interaction study
Aim: A reliable, sensitive and simple LC-MS/MS method has been established and validated for the quantitation of rivaroxaban (RIV) and metformin (MET) in rat plasma. Results: The procedure of method validation was conducted according to the guiding principles of EMA and US FDA. At the same time, the method was applied to pharmacokinetic interactions study between RIV and MET for the first time. When RIV and MET coadministered to rats, pharmacokinetic parameters of MET like AUC(0-t), AUC(0-∞) and Cmax had statistically significant increased. tmax of RIV was prolonged without affecting t1/2 obviously and Cmax was inhibited significantly (p < 0.05) by comparison to the single group. Conclusion: The results indicated that drug-drug interactions occurred when the coadministration of RIV and MET.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Bioanalysis - 11(2019), 24 vom: 25. Dez., Seite 2269-2281 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gai, Shouchang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9100L32L2N |
|---|
| Anmerkungen: |
Date Completed 21.04.2020 Date Revised 21.04.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2019-0230 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30446516X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30446516X | ||
| 003 | DE-627 | ||
| 005 | 20231225115038.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2019-0230 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1014.xml |
| 035 | |a (DE-627)NLM30446516X | ||
| 035 | |a (NLM)31845601 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gai, Shouchang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a LC-MS/MS method for simultaneous determination of rivaroxaban and metformin in rat plasma |b application to pharmacokinetic interaction study |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.04.2020 | ||
| 500 | |a Date Revised 21.04.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: A reliable, sensitive and simple LC-MS/MS method has been established and validated for the quantitation of rivaroxaban (RIV) and metformin (MET) in rat plasma. Results: The procedure of method validation was conducted according to the guiding principles of EMA and US FDA. At the same time, the method was applied to pharmacokinetic interactions study between RIV and MET for the first time. When RIV and MET coadministered to rats, pharmacokinetic parameters of MET like AUC(0-t), AUC(0-∞) and Cmax had statistically significant increased. tmax of RIV was prolonged without affecting t1/2 obviously and Cmax was inhibited significantly (p < 0.05) by comparison to the single group. Conclusion: The results indicated that drug-drug interactions occurred when the coadministration of RIV and MET | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a LC–MS/MS | |
| 650 | 4 | |a metformin | |
| 650 | 4 | |a pharmacokinetic interactions | |
| 650 | 4 | |a rivaroxaban | |
| 650 | 7 | |a Factor Xa Inhibitors |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Metformin |2 NLM | |
| 650 | 7 | |a 9100L32L2N |2 NLM | |
| 650 | 7 | |a Rivaroxaban |2 NLM | |
| 650 | 7 | |a 9NDF7JZ4M3 |2 NLM | |
| 700 | 1 | |a Huang, Anli |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Tian |e verfasserin |4 aut | |
| 700 | 1 | |a Gou, Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xingchen |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Chunling |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Hongyun |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Dapeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Binbin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Libin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 11(2019), 24 vom: 25. Dez., Seite 2269-2281 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:24 |g day:25 |g month:12 |g pages:2269-2281 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2019-0230 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 24 |b 25 |c 12 |h 2269-2281 | ||